CommercialAdministrativeLow impact
08.01.39d, Cerliponase alfa (Brineura®)
Independence Blue Cross·Pediatrics, Neurology·Pharmacy
Effective date
Dec 10, 2025
We identified it
Jun 19, 2026
Summary
The Cerliponase alfa (Brineura®) pharmacy policy has been reissued and is effective December 10, 2025. This appears to be a routine policy reissuance for a specialized medication used to treat neuronal ceroid lipofuscinosis type 2 (CLN2 disease), a rare pediatric condition.
Action Required
By December 10, 2025: Billing team should review the updated Cerliponase alfa (Brineura®) policy details at the provided URL to identify any changes in prior authorization requirements, coverage criteria, or billing procedures for this rare disease medication. Contact the payer directly if currently billing for this medication to confirm continued coverage requirements.